Get the Stockscreener App
221.20
0.63%
1.39
After Hours:
220.77
-0.43
-0.19%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Danaher Corp stock is traded at $221.20, with a volume of 3.00M.
It is up +0.63% in the last 24 hours and up +10.52% over the past month.
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
See More
Previous Close:
$219.81
Open:
$220.72
24h Volume:
3.00M
Relative Volume:
0.73
Market Cap:
$155.50B
Revenue:
$24.78B
Net Income/Loss:
$3.68B
P/E Ratio:
42.75
EPS:
5.1743
Net Cash Flow:
$5.29B
1W Performance:
-0.00%
1M Performance:
+10.52%
6M Performance:
+16.66%
1Y Performance:
+9.26%
1-Day Range:
$219.11
$221.42
1-Week Range:
$211.72
$227.61
52-Week Range:
$160.93
$242.80
Danaher Corp Stock (DHR) Company Profile
Name
Danaher Corp
Sector
Industry
Phone
(202) 828-0850
Address
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
221.20 | 155.50B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
662.24 | 244.86B | 45.20B | 6.87B | 6.75B | 18.19 |
NTRA
Natera Inc
|
397.77 | 57.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
171.33 | 48.30B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
262.21 | 43.16B | 16.63B | 1.39B | 2.12B | 8.0674 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-26 | Resumed | UBS | Buy |
| Jun-11-26 | Initiated | Piper Sandler | Neutral |
| Jun-03-26 | Initiated | DZ Bank | Buy |
| Jun-02-26 | Resumed | Wolfe Research | Peer Perform |
| May-26-26 | Resumed | Citigroup | Buy |
| May-15-26 | Resumed | RBC Capital Mkts | Outperform |
| Dec-09-25 | Initiated | Goldman | Buy |
| Dec-02-25 | Initiated | Morgan Stanley | Overweight |
| Oct-08-25 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jul-11-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Apr-10-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Mar-14-25 | Upgrade | Stifel | Hold → Buy |
| Feb-03-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Dec-19-24 | Initiated | Guggenheim | Buy |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-31-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-18-23 | Initiated | HSBC Securities | Hold |
| Dec-13-23 | Resumed | Wolfe Research | Peer Perform |
| Dec-07-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-01-23 | Initiated | SVB Securities | Outperform |
| Apr-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-18-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-05-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Oct-24-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-17-22 | Resumed | Bernstein | Outperform |
| Jul-20-22 | Initiated | UBS | Buy |
| Jun-01-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-11-22 | Initiated | Bernstein | Outperform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-10-21 | Reiterated | BofA Securities | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Reiterated | Goldman | Buy |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Apr-07-21 | Resumed | Robert W. Baird | Outperform |
| Mar-03-21 | Resumed | Barclays | Overweight |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-25-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jun-16-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-02-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-26-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-03-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Resumed | Stifel | Hold |
| Oct-28-19 | Reiterated | Needham | Buy |
| Oct-14-19 | Resumed | Credit Suisse | Outperform |
| Jul-19-19 | Reiterated | Needham | Buy |
| Jun-11-19 | Initiated | Piper Jaffray | Neutral |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| Apr-17-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Reiterated | Needham | Buy |
| Feb-25-19 | Upgrade | Janney | Neutral → Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Apr-20-18 | Reiterated | Stifel | Buy |
View All
Danaher Corp Stock (DHR) Latest News
Danaher stock at USD 219.87 on October 9, 2026 - AD HOC NEWS
Danaher accelerates Life Sciences research with new AI-powered autonomous lab - BioSpectrum Asia
Danaher Corp. stock at EUR 196.80, market value USD 154.7 billion - AD HOC NEWS
Barclays raises target for Danaher stock to USD 255.00 - AD HOC NEWS
Did Danaher’s (DHR) New AI-Powered Autonomous Lab at Abcam Just Redefine Its Innovation Edge? - Yahoo Finance
Danaher (DHR) Stock May Be 4% Undervalued Despite AI Lab Launch - Yahoo Finance
Is Danaher (DHR) Undervalued As Its New AI Lab Pushes Faster Antibody Development? - Yahoo Finance
Danaher (DHR) Launched Its First AI Powered Autonomous Laboratory - Yahoo Finance
Danaher Accelerates Life Sciences Research with New AI-powered Autonomous Lab - HPCwire
Venkatesan leaves head of investment role at Danaher - Global Venturing
Danaher Corp. stock outperforms competitors on strong trading day - MarketWatch
Life sciences firm Danaher to launch AI-powered autonomous research lab in 2027 - Reuters
Top Stock Reports for AMD, Palo Alto & ConocoPhillips - Zacks Investment Research
Danaher is launching an AI-powered autonomous lab for drug discovery - Quartz
Danaher stock rises 2% on AI-powered autonomous lab plans - Yahoo Finance
Danaher Corporation Announces Plans to Launch Its First Ai-Powered Autonomous Lab - marketscreener.com
Danaher to Launch AI-Backed Autonomous Lab - www.marketscreener.com
Life sciences firm Danaher to launch AI-powered autonomous research lab in 2027 - The Lufkin Daily News
Life sciences firm Danaher to launch AI-powered autonomous research lab in 2027 - Wichita Eagle
Life sciences firm Danaher to launch AI-powered autonomous research lab in 2027 - marketscreener.com
Danaher plans AI-powered autonomous lab for antibody research By Investing.com - Investing.com Canada
Danaher launches AI-powered autonomous lab to s... - Pluang
A planned lab could make up to 10 times as many research tools each year as it scales. - Stock Titan
Danaher Accelerates Life Sciences Research with New AI-powered Autonomous Lab - Yahoo Finance
Danaher Accelerates Life Sciences Research with New AI-powered Autonomous Lab - TradingView
Danaher (DHR) Draws Fresh RBC Backing, Is The Valuation Still Compelling? - Simply Wall Street
Danaher Corp. stock outperforms competitors despite losses on the day - MarketWatch
Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.
RBC Capital raises Danaher stock price target on peer valuation By Investing.com - Investing.com South Africa
Danaher Corp (DHR) Stock Up 3.3% and Still Undervalued -- GF Sco - GuruFocus
Danaher Corporation stock reports 5.5 percent revenue growth for Q2 2026 - AD HOC NEWS
Danaher Corp. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
DHR|Danaher Corp|Price:221.230|Chg%:+7.170 - TradingKey
Danaher Corp Stock (DHR) Moved Up by 3.32% on Oct 5: What Investors Need To Know - TradingKey
Danaher Corporation, Illumina, Reliance - TradingView
Danaher Corporation, Illumina, Reliance - TradingView
Danaher's Multiple Now in Line With Peers, RBC Says - marketscreener.com
Danaher's Multiple Now in Line With Peers, RBC Says - Yahoo Finance
Europe Point of Care Diagnostics Market Size and Forecast, 20212031 | Market to Reach US$21.4 Billion by 2031 as Rapid Testing and Molecular Innovation Drive 13.4% CAGR - GlobeNewswire Inc.
Danaher Corporation, Illumina, Reliance - TradingView
Global Oligonucleotide Synthesis Reagents Market Size, Share, and Forecast, 2026-2033 | Therapeutics Demand Fuels 11.9% CAGR and USD 1.75 Billion Opportunity - GlobeNewswire Inc.
Cell and Gene Therapy Biomanufacturing MarketSize, Share, and Forecast, 2026-2031 | Automation, Viral Vectors, and CDMO Expansion Drive 11.7% CAGR to $8.7 Billion - GlobeNewswire Inc.
Magnetic Beads MarketGlobal Forecast and Growth Opportunities, 2026-2032 | Automation, Genomics, and Molecular Diagnostics Drive 7.91% CAGR Toward USD 6.18 Billion - GlobeNewswire Inc.
DANAHER CORPORATION : RBC RAISES TARGET PRICE TO $250 FROM $215 - Moomoo
Options on 36,856 shares at $194.78 are among the Danaher (DHR) strategy chief's holdings. - Stock Titan
DANAHER CORP (DHRC.VI) Q2 FY2026 earnings call transcript - Yahoo Finance
Parker-Hannifin Benefits From Business Strength Amid Headwinds - Zacks Investment Research
Danaher Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Danaher Slides as Investors Weigh Leadership Change and Prior Growth Outlook Reset - Quiver Quantitative
Danaher Corp Stock (DHR) Moved Down by 3.29% on Oct 1: What Investors Need To Know - TradingKey
Danaher Corp Stock (DHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Danaher Corp Stock (DHR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rainer M. Blair | Officer |
Aug 21 '26 |
Proposed Sale |
218.85 |
58,255 |
12,749,107 |
0 |
| Zerhouni Elias A. | Director |
Jul 15 '26 |
Option Exercise |
71.88 |
3,298 |
237,060 |
46,484 |
| FILLER LINDA | Director |
Jul 15 '26 |
Option Exercise |
71.88 |
3,298 |
237,060 |
28,010 |
| SCHWIETERS JOHN T | Former Director |
Jul 14 '26 |
Proposed Sale |
199.59 |
3,298 |
658,254 |
0 |
| SPOON ALAN G | Director |
May 01 '26 |
Proposed Sale |
174.67 |
1,358 |
237,207 |
0 |
| SPOON ALAN G | Director |
May 01 '26 |
Option Exercise |
71.88 |
3,298 |
237,060 |
125,452 |
| SPOON ALAN G | Director |
May 01 '26 |
Sale |
174.67 |
1,358 |
237,207 |
124,094 |
| Milosevich Gregory M | Executive Vice President |
Feb 19 '26 |
Option Exercise |
58.59 |
1,320 |
77,339 |
6,419 |
| Milosevich Gregory M | Executive Vice President |
Feb 19 '26 |
Sale |
208.01 |
1,320 |
274,575 |
5,099 |
| Milosevich Gregory M | Officer |
Feb 19 '26 |
Proposed Sale |
208.01 |
1,320 |
274,575 |
0 |
0.64%
0.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):